Investigating the Accuracy of the openFDA API using the FDA Adverse Event Reporting System (FAERS)

被引:0
|
作者
Shin, Jennifer [1 ]
机构
[1] 8 Path Solut LLC, New York, NY 10024 USA
来源
2014 IEEE INTERNATIONAL CONFERENCE ON BIG DATA (BIG DATA) | 2014年
关键词
openFDA; FDA; adverse events; FDA Adverse Events Reporting System; FAERS; SURVEILLANCE;
D O I
暂无
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) is a database that contains information on adverse event and medication error reports submitted to the FDA. Each quarter the FDA releases the data to the public, but accessing the data requires researchers to download, import, and consolidate data for every quarter starting from 2004. In an effort to provide easier access to this, the FDA launched the openFDA initiative in June 2014, which gives the public API access to information about adverse events reports. Although the API enables easier access to the FAERS data, the quality of the API design and the features of the data set will determine the reliability of the information retrieved. Thus, errors in the API can result in inaccurate and unreliable data analysis. Furthermore, the number of adverse events reports retrieved by the API for a particular drug can differ from the FAERS data files due to the openFDA harmonization process and the existence of multiple entries and variations for any given drug name in the FAERS data files. Since there are no universal rule that can be used to identify errors or potential issues, we propose evaluating the openFDA API by searching for a particular drug (brand name), Yaz, and the generic name, Drospirenone Ethinyl Estradiol, and comparing the results against the FAERS data files. Our results show that in the case of Yaz, the openFDA API and the drug harmonization process is inaccurate and inconsistent.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database
    Zhu, Jinfeng
    Hu, Mianda
    Liang, Yingshi
    Zhong, Mingjun
    Chen, Zilin
    Wang, Zhenjie
    Yang, Yujia
    Luo, Ziyi
    Zeng, Wenqi
    Li, Jiahui
    Du, Yikuan
    Liu, Yi
    Yang, Chun
    HELIYON, 2024, 10 (14)
  • [22] Indication and adverse event profiles of denosumab and zoledronic acid: based on US FDA adverse event reporting system (FAERS)
    Su, Si
    Wu, Liuqing
    Zhou, Guibao
    Peng, Lingling
    Zhao, Huanzhe
    Wang, Xiao
    Li, Kuan
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [23] A disproportionality analysis of adverse events associated with loop diuretics in the FDA Adverse Event Reporting System (FAERS)
    Xue, Zehu
    Liu, Xi
    Liu, Qifeng
    Yang, Xiuming
    Yu, Lixia
    BMC PHARMACOLOGY & TOXICOLOGY, 2025, 26 (01):
  • [24] A real-world analysis of safety profile of selexipag by using FDA adverse Event Reporting System (FAERS)
    Zhao, Jie
    Wang, Mei
    Yu, Qing
    Yang, Yi
    Zhang, Bin
    Zhan, Sanhua
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (07) : 937 - 948
  • [25] Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS)
    Kong, Wenqiang
    Mao, Wei
    Zhang, Lin
    Wu, Yanyan
    FRONTIERS IN PEDIATRICS, 2023, 10
  • [26] Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS)
    Wittayanukorn, Saranrat
    Qian, Jingjing
    Johnson, Brandon S.
    Hansen, Richard A.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2017, 23 (02) : 93 - 102
  • [27] A Review of Drug Reaction with Eosinophilia and Systemic Symptoms in the FDA Adverse Event Reporting System FAERS)
    Bluestein, Sara
    Yu, Roger
    Stone, Cosby
    Phillips, Elizabeth
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB12 - AB12
  • [28] A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) for gemcitabine
    Zhang, Cheng
    Li, Ke
    Xu, Shu-Ning
    Qiao, Lei
    Ren, Yu-Lin
    Li, Qun
    Liu, Ying
    EXPERT OPINION ON DRUG SAFETY, 2025, 24 (03) : 365 - 376
  • [29] Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
    Zhou, Jianxing
    Wei, Zipeng
    Xu, Baohua
    Liu, Maobai
    Xu, Ruichao
    Wu, Xuemei
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [30] Pediatric drug-induced anaphylaxis reports in the FDA Adverse Event Reporting System (FAERS)
    Brameli, Anna
    Yuan, Irene H.
    Phillips, Elizabeth J.
    Stone Jr, Cosby A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2024, 12 (09):